Press release
Global Respiratory Inhalers Market is projected to reach USD 51,132.25 million by 2032, estimates DelveInsight
Global Respiratory Inhalers Market
According to DelveInsight's latest analysis, the global demand for respiratory inhalers is accelerating, fueled by several converging factors. The primary driver is the increasing prevalence of respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), bronchitis, and bronchospasm. These conditions continue to affect a growing portion of the global population, creating an urgent need for rapid and effective treatment options. At the same time, rising patient awareness regarding early diagnosis, disease management, and adherence to treatment protocols is further supporting market growth.
Moreover, ongoing research and development initiatives, alongside frequent product innovations by leading pharmaceutical and medical device companies, are strengthening the expansion of the respiratory inhaler market.
DelveInsight's "Respiratory Inhalers Market Insights, Competitive Landscape, and Market Forecast-2032" report offers a comprehensive view of current and future market trends, upcoming device innovations, challenges, market drivers, and barriers. The report also highlights major emerging products and profiles of key companies active in the respiratory inhalers market.
Learn why North America is leading market growth in the respiratory inhaler segment: Respiratory Inhalers Market Trends Snapshot @ https://www.delveinsight.com/sample-request/respiratory-inhalers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Overview of Respiratory Inhalers
Respiratory inhalers are specialized medical devices designed to deliver medication directly to the lungs, providing effective management for conditions such as asthma, COPD, and other respiratory disorders. By allowing patients to inhale medication in the form of a mist, aerosol, or dry powder, these devices provide fast, targeted relief. Common inhaler types include metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and soft mist inhalers (SMIs). These devices are critical for both emergency symptom relief and long-term disease management, helping patients manage wheezing, shortness of breath, and airway inflammation.
Respiratory Inhalers Market Size and Forecast
DelveInsight estimates the respiratory inhalers market was valued at approximately USD 35.36 billion in 2024, and it is expected to grow at a CAGR of 4.65% between 2025 and 2032, reaching around USD 51.13 billion by 2032.
Respiratory Inhalers Market Dynamics and Regional Insights
North America is poised to lead the global respiratory inhaler market in 2024, driven by a combination of high prevalence of asthma, COPD, and bronchitis, increasing demand for rapid-acting drug delivery solutions, and significant product innovation from major players. The availability of new, fast-acting inhalation therapies that improve patient adherence and provide rapid symptom relief is further strengthening market expansion in the region.
Discover the latest trends shaping the Respiratory Inhalers Market: Respiratory Inhalers Insights Snapshot - https://www.delveinsight.com/sample-request/respiratory-inhalers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Recent Developments in the Market
Several recent product launches and regulatory approvals are driving growth in the respiratory inhalers market:
• May 2024: Amphastar Pharmaceuticals, Inc. received FDA approval for Albuterol Sulfate Inhalation Aerosol (formerly AMP-008) for the treatment and prevention of bronchospasm in patients aged four years and older, including exercise-induced bronchospasm.
• June 2024: Verona Pharma plc's Ohtuvayre (ensifentrine) gained FDA approval for maintenance treatment of COPD in adults, marking the first inhaled therapy with a novel mechanism of action approved for COPD maintenance in over two decades.
• July 2023: Lupin launched Luforbec® 100/6 (beclometasone 100 μg / formoterol 6 μg) via pMDI for adult asthma and COPD patients in Germany.
• April 2022: GlaxoSmithKline Pharmaceuticals Limited introduced Trelegy Ellipta in India, the country's first single-inhaler triple therapy (SITT) for COPD, enabling convenient once-daily dosing.
These developments highlight the continuous innovation in inhaler therapies that is driving market expansion globally.
Key Players in the Respiratory Inhalers Market
The global respiratory inhalers market is highly competitive, with major Respiratory Inhalers companies including:
• Pharmaceutical Companies: Novartis AG, AstraZeneca, GSK plc, CHIESI Farmaceutici S.p.A., Lupin, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, Merck & Co., Inc., Organon Group, Viatris Inc., Sumitomo Pharma Co., Ltd., Cipla, Verona Pharma plc.
• Medical Device Companies: OMRON Corporation, Koninklijke Philips N.V., BPL Medical Technologies, Rossmax International Ltd., AptarGroup, Inc.
Explore key MedTech innovators shaping the respiratory inhalers market: Key Respiratory Inhalers Companies - https://www.delveinsight.com/sample-request/respiratory-inhalers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Market Landscape and Innovation
Given the increasing global burden of respiratory diseases, leading pharmaceutical companies are investing heavily in R&D to develop advanced inhaler therapies. Notably, AstraZeneca's Trixeo Aerosphere, approved in the UK in May 2025, is a triple-combination MDI containing budesonide, glycopyrronium, and formoterol fumarate. This inhaler, aimed at adults with moderate to severe COPD, improves lung function while reducing the risk of exacerbations, representing a significant advancement in combination inhalation treatments.
The clinical benefits, coupled with rising disease prevalence and ongoing product innovation, are expected to drive strong growth in the metered-dose inhaler segment, contributing substantially to overall respiratory inhalers market expansion during the 2025-2032 forecast period.
Scope of the Respiratory Inhalers Market Report
• Global Coverage: North America, Europe, Asia-Pacific, and Rest of the World
• Study Period: 2022-2032
• Respiratory Inhalers Market Segmentation by Product Type: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Soft Mist Inhalers (SMIs), and Nebulizers (Jet, Mesh, Ultrasonic)
• Respiratory Inhalers Market Segmentation by Device Type: Conventional and Smart Inhalers
• Respiratory Inhalers Market Segmentation by Indication: Asthma, COPD, Others
• Segmentation by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• Key Insights: Porter's Five Forces Analysis, Product Profiles, Case Studies, Key Opinion Leader Views, Analyst Opinions
Want to see how the Respiratory Inhalers market will evolve by 2032? Get a detailed snapshot:
Respiratory Inhalers Market Analysis - https://www.delveinsight.com/sample-request/respiratory-inhalers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Respiratory Inhalers Market is projected to reach USD 51,132.25 million by 2032, estimates DelveInsight here
News-ID: 4297395 • Views: …
More Releases from DelveInsight Business Research
Limbal Stem Cell Deficiency Market to Surpass USD 2.6 Billion by 2034, Driven by …
In 2023, the Limbal Stem Cell Deficiency (LSCD) market was dominated by the United States, generating nearly USD 1.5 billion in revenue, while Spain represented the smallest market with approximately USD 127 million. This regional distribution is expected to remain consistent throughout the forecast timeline. The US accounted for nearly 103,000 diagnosed LSCD cases, whereas Japan recorded around 37,000 cases, with both countries projected to witness notable growth in patient…
SSc-ILD Market Set to Cross USD 750 Million by 2034, Driven by 10+ Emerging Ther …
The major players operating in the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market include Roche, Prometheus Biosciences, Inc., Merck, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, among others.
DelveInsight's report titled "Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Forecast-2034" delivers a comprehensive analysis of SSc-ILD, covering historical data, projected epidemiology, and evolving market trends across the United States, EU4 (Germany, Spain, Italy, and France),…
Developmental and Epileptic Encephalopathy Treatment Market Poised for Accelerat …
The Developmental and Epileptic Encephalopathy (DEE) treatment market across the seven major markets (7MM) was valued at nearly USD 2.1 billion in 2023 and is expected to register a healthy compound annual growth rate over the forecast period. The United States emerged as the largest contributor, capturing close to 80% of the overall market revenue.
The DEE treatment landscape is undergoing a significant transformation as the limitations of traditional antiepileptic drugs…
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ Therapies and 8+ Co …
DelveInsight's "Polycythemia Vera Pipeline Insight 2025" report delivers an in-depth overview of the Polycythemia Vera pipeline landscape, covering more than 8 companies and 10+ pipeline candidates. The report analyzes both clinical-stage and preclinical assets, offering detailed drug profiles across various stages of development. It also evaluates Polycythemia Vera therapies based on product classification, development stage, route of administration, and molecular category, while additionally spotlighting inactive or discontinued pipeline assets.
Explore the…
More Releases for Inhalers
North America Leads the Surge in Metered-Dose Inhalers Market Adoption | Metered …
The Global Metered-Dose inhalers Market reached US$ 16.6 billion in 2023 and is expected to reach US$ 24.18 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2025-2033.
The Metered-Dose Inhalers (MDI) Market focuses on drug delivery devices used in managing respiratory disorders like asthma and COPD. MDIs provide precise, portable, and fast-acting medication administration. The market is expanding due to growing respiratory disease incidence and environmental…
Inhalers Market Analysis-Growth Projections
The Inhalers Market is expected to register a CAGR of 5.3% from 2025 to 2031
Download PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00021658?utm_source=OpenPR&utm_medium=10392
Market leaders and key company profiles
3M
Agilent Technologies
GlaxoSmithKline
Novartis
Propeller Health
Boehringer Ingelheim
BESPAK
AstraZeneca
Cohero Health
Segments Covered By Devices
Metered Dose Inhalers
Dry Powder Inhalers
Nebulizers
Nasal Inhalers
By Type
Preventive Inhalers
Reliever Inhalers
Long-Acting Bronchodilators Inhalers
By Application
Asthma
Chronic Obstructive Pulmonary Diseases
Others
By End User
Home Care
Hospitals and Clinics
Others
Contact Us:
Contact Person: Ankit Mathur
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
About US
The Insight Partners is a one stop industry research provider of actionable intelligence. We help…
Inhalers Market Size 2024 to 2031.
Market Overview and Report Coverage
The Inhalers Market refers to the pharmaceutical devices used for delivering medications directly into the lungs, thereby providing quick relief for respiratory conditions such as asthma and COPD. The market is expected to witness substantial growth over the forecasted period, with a projected CAGR of 9.30%.
Several factors are driving this growth, including the increasing prevalence of respiratory diseases worldwide, rising awareness about the…
Dry Powder Inhalers Market - Breathe Freely: Dry Powder Inhalers Empowering Asth …
Newark, New Castle, USA: The "Dry Powder Inhalers Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Dry Powder Inhalers Market: https://www.growthplusreports.com/report/dry-powder-inhalers-market/8762
This latest report researches the industry structure,…
Smart Inhalers Market Boosting The Growth Worldwide
Precision Business Insights published a research report on “Smart Inhalers Market By Product Type (Inhalers, Metered dose inhalers, Dry powder inhalers, Nebulizers), By Application (COPD and Asthma), By Distribution channel (Hospitals, Retail pharmacies and Online pharmacies) - Global/Region/Country Forecast to 2028”.
Smart inhalers, also known as connected inhalers and sensors, are typically used as clip-on sensors on top of a normal nebulizer for the medication of COPD and asthma.…
Smart Inhaler Market - Industry Analysis, Size, Share, Growth, Trends, and Forec …
The Smart Inhaler Market is projected to gain market revenue of US$ 4,563.1 million by 2026, growing at a CAGR of 15.72% during the forecast period 2020-2026. Owing to the rising adoption of Smart Inhaler services due to the rapid increase in the aging population along with respiratory disorders associated with them. Moreover, increasing incidence of respiratory diseases, the rise in air pollution, and growth in healthcare burden owing to…
